|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|||
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|||
|
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|||
| (1) |
On January 23, 2026, the Nasdaq Stock Market LLC (“
|
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
||
|
|
☒
|
Smaller reporting company
|
|
||
|
Emerging growth company
|
|
|
Page
|
||
|
PART I
|
||
|
1
|
||
|
10
|
||
|
10
|
||
|
10
|
||
|
13
|
||
|
13
|
||
|
13
|
||
|
PART II
|
||
|
14
|
||
|
14
|
||
|
15
|
||
|
27
|
||
|
28
|
||
| 91 | ||
| 91 | ||
| 92 | ||
| 92 | ||
|
PART III
|
||
| 93 | ||
| 96 | ||
| 100 | ||
| 102 | ||
| 104 | ||
|
PART IV
|
||
| 105 | ||
| 110 | ||
| 111 | ||
| • |
Level 0—No Driving Automation: In this level, the human is fully responsible for all dynamic driving tasks (“DDT”) at all times, even if an active safety
system assists in the task. “L0” is defined as driver support features that are limited to warnings or momentary emergency intervention. Examples of warnings include blind spot warning or lane departure warnings. Examples of features with
momentary assistance include automated emergency braking (“AEB”) and lane keep assist (“LKA”).
|
| • |
Level 1—Driver Assistance: In this level, while the human is fully responsible for all DDT at all times, an active safety system may assist by executing either the longitudinal or the lateral
vehicle motion control subtask, and disengages immediately upon driver request. Examples include lane centering support (“LCS”) or the more widely adopted adaptive cruise control (“ACC”). These features are viewed as comfort features, easing
the driving load from the driver during extended highway drives.
|
| • |
Level 2—Partial Driving Automation: In this level, the human is fully responsible for all DDT at all times, even if an active safety system assists in the task. When the controls from an L1 system
are operated by the vehicle simultaneously, such as LCS and ACC, the system is then classified as L2.
The term L2+, while not an officially recognized term, is often used for today’s higher capability L2 systems, many of which add a driver monitoring system, such as camera or steering wheel sensing to ensure the human driver remains
engaged, but require that the driver remain attentive at all times. This is considered by safety experts as a challenging phase because the systems may work well for long periods of time, and can lull drivers into trust and complacency.
|
| • |
Level 3—Conditional Driving Automation: In this level, the automated driving system (“ADS”) performs the entire DDT while engaged. The driver is
responsible to verify the operational readiness of the ADS, determine whether to engage the system, and becomes the fallback-ready user when the ADS is engaged. The ADS permits engagement and operation only within its operational design
domain (“ODD”). However, the ODD is often limited to highway applications within certain speed parameters. An example is a traffic jam assist feature that allows the driver to stop paying attention for short periods of time at lower speeds.
|
|
•
|
Level 4—High Driving Automation: In this level, the ADS performs the entire DDT while engaged. The driver is responsible to verify the operational
readiness of the ADS, determine whether to engage the system, and becomes a passenger when the ADS is engaged (when physically present in the vehicle). The ADS permits engagement and operation only within its ODD. The ODD is expanded in
this level to include numerous different driving environments, such as highway and urban.
|
| • |
Level 5—Full Driving Automation: In this level, the ADS performs the entire DDT while engaged. It is the designation for vehicles that, when placed in
automated driving mode, can drive everywhere and in all conditions without human intervention or even occupants.
|
| • |
adoption of frameworks established by the National Institute of Standards and Technology (“NIST”) and International Organization for Standardization (“ISO”) for a flexible, tailored, and risk-based approach
to cybersecurity, helping to ensure a continuous process of identifying, protecting, detecting, responding, and recovering from cyber incidents;
|
| • |
alignment with ISO 21434 (automotive security) and ISO 27001 (information security management) standards, addressing cybersecurity aspects of automotive products and the broader information security
management system to establish, implement, maintain, and continually improve confidentiality, integrity, and availability, as well as meeting the cybersecurity standards and product requirements established by our OEM customers;
|
| • |
conducting regular network and endpoint monitoring, vulnerability assessments, and penetration testing to improve our information systems;
|
| • |
providing cybersecurity training programs for employees, management, and directors, including conducting periodic phishing tests to promote awareness for all employees and all contractors with access to
corporate email systems;
|
| • |
leveraging industry best practices for incident handling to help identify, protect, detect, respond, and recover when there is an actual or potential cybersecurity incident, and participating in an industry
information sharing and analysis center;
|
| • |
employing threat intelligence monitoring processes to model, research, and respond to cyber threats in a proactive manner;
|
| • |
closely monitoring emerging data protection laws and implementing changes to our processes accordingly;
|
| • |
undertaking a periodic review of public-facing policies and statements related to cybersecurity;
|
| • |
carrying information security risk insurance that may provide some protection against the potential losses arising from a cybersecurity incident; and
|
| • |
tracking key performance indicators pertaining to cybersecurity incidents, response and recovery, vulnerabilities, and risks.
|
|
Location
|
Principal Use
|
Square Footage
|
Lease Expiration Date
|
|||
|
Orlando, Florida
|
Corporate headquarters, manufacturing, and administrative functions
|
67,883
|
6/30/2026
|
|||
|
Orlando, Florida
|
Testing
|
207,487
|
3/31/2028
|
|||
|
Mexico
|
Manufacturing
|
220,873
|
8/31/2032
|
|||
|
Sunnyvale, California
|
Research and development and administration functions
|
13,617
|
3/31/2028
|
|||
|
Santa Barbara, California
|
Semiconductor research and development
|
20,337
|
11/30/2026
|
|||
|
Colorado Springs, Colorado
|
Semiconductor research and development
|
8,126
|
3/31/2028
|
|||
|
Cranbury, New Jersey
|
Semiconductor research and development
|
16,464
|
3/14/2028
|
|||
|
Bedford, Massachusetts
|
Manufacturing, engineering and administrative functions
|
19,332
|
8/31/2028
|
|||
|
Wilmington, Massachusetts
|
Semiconductor fabrication
|
7,573
|
1/30/2030
|
|||
|
Bloomington, Minnesota
|
Product design and engineering
|
25,953
|
4/30/2029
|
|||
|
Germany
|
Research and development
|
17,405
|
3/15/2029
|
|||
|
India
|
Research and development and administration functions
|
8,000
|
9/14/2029
|
| • |
Personnel-related expenses, including salaries, benefits, and stock-based compensation expense, for personnel in our research and engineering functions;
|
| • |
Expenses related to materials, software licenses, supplies, data labeling and other third-party services;
|
| • |
Prototype expenses; and
|
| • |
An allocated portion of facility and IT costs and depreciation.
|
|
Year Ended December 31,
|
Change
|
Change
|
||||||||||||||
|
2025
|
2024
|
$ |
%
|
|||||||||||||
|
Revenue
|
$
|
66,014
|
$
|
75,395
|
$
|
(9,381
|
)
|
(12
|
)%
|
|||||||
|
Cost of sales
|
144,232
|
101,085
|
43,147
|
43
|
%
|
|||||||||||
|
Gross loss
|
(78,218
|
)
|
(25,690
|
)
|
(52,528
|
)
|
204
|
%
|
||||||||
|
Operating Expenses:
|
||||||||||||||||
|
Research and development
|
137,592
|
231,669
|
(94,077
|
)
|
(41
|
)%
|
||||||||||
|
Sales and marketing
|
16,619
|
45,488
|
(28,869
|
)
|
(63
|
)%
|
||||||||||
|
General and administrative
|
25,968
|
115,771
|
(89,803
|
)
|
(78
|
)%
|
||||||||||
|
Impairment of goodwill and intangible assets
|
3,719
|
6,647
|
(2,928
|
)
|
(44
|
)%
|
||||||||||
|
Impairment of long-lived assets
|
7,513
|
—
|
7,513
|
100
|
%
|
|||||||||||
|
Restructuring and other costs
|
27,172
|
9,772
|
17,400
|
178
|
%
|
|||||||||||
|
Total operating expenses
|
218,583
|
409,347
|
(190,764
|
)
|
(47
|
)%
|
||||||||||
|
Loss from operations
|
(296,801
|
)
|
(435,037
|
)
|
138,236
|
(32
|
)%
|
|||||||||
|
Other income (expense), net:
|
||||||||||||||||
|
Change in fair value of warrant liabilities
|
—
|
1,069
|
(1,069
|
)
|
(100
|
)%
|
||||||||||
|
Interest expense
|
(48,190
|
)
|
(27,032
|
)
|
(21,158
|
)
|
78
|
%
|
||||||||
|
Interest income
|
4,488
|
10,418
|
(5,930
|
)
|
(57
|
)%
|
||||||||||
|
Gain on extinguishment of debt
|
22,303
|
148,660
|
(126,357
|
)
|
(85
|
)%
|
||||||||||
|
(Loss) gain from acquisition of EM4
|
(48
|
)
|
1,474
|
(1,522
|
)
|
(103
|
)%
|
|||||||||
|
Changes in fair value of derivative liability
|
(3,308
|
)
|
31,729
|
(35,037
|
)
|
(110
|
)%
|
|||||||||
|
Losses and impairments related to investments and certain other assets, and other income (expense)
|
1,941
|
(5,164
|
)
|
7,105
|
(138
|
)%
|
||||||||||
|
Total other income (expense), net
|
(22,814
|
)
|
161,154
|
(183,968
|
)
|
(114
|
)%
|
|||||||||
|
Loss before reorganization items and provision for (benefit from) income taxes
|
(319,615
|
)
|
(273,883
|
)
|
(45,732
|
)
|
17
|
%
|
||||||||
|
Reorganization items
|
46,349
|
—
|
46,349
|
100
|
%
|
|||||||||||
|
Provision for (benefit from) income taxes
|
338
|
(743
|
)
|
1,081
|
(145
|
)%
|
||||||||||
|
Net loss
|
$
|
(366,302
|
)
|
$
|
(273,140
|
)
|
$
|
(93,162
|
)
|
34
|
%
|
|||||
|
Year Ended December 31,
|
Change
|
Change
|
||||||||||||||
|
2025
|
2024
|
$ |
%
|
|||||||||||||
|
Revenue from sales to external customers:
|
||||||||||||||||
|
Autonomy Solutions
|
$
|
40,884
|
$
|
53,480
|
$
|
(12,596
|
)
|
(24
|
)%
|
|||||||
|
ATS
|
25,130
|
21,915
|
3,215
|
15
|
%
|
|||||||||||
|
Total
|
$
|
66,014
|
$
|
75,395
|
$
|
(9,381
|
)
|
(12
|
)%
|
|||||||
|
Year Ended December 31,
|
Change
|
Change
|
||||||||||||||
|
2025
|
2024
|
$ |
%
|
|||||||||||||
|
Segment operating loss
|
||||||||||||||||
|
Autonomy Solutions
|
$
|
(281,587
|
)
|
$
|
(412,998
|
)
|
$
|
131,411
|
(32
|
)%
|
||||||
|
ATS
|
(15,214
|
)
|
(22,039
|
)
|
6,825
|
(31
|
)%
|
|||||||||
|
Year Ended December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Net cash provided by (used in):
|
||||||||
|
Operating activities
|
$
|
(196,454
|
)
|
$
|
(276,630
|
)
|
||
|
Investing activities
|
96,811
|
42,463
|
||||||
|
Financing activities
|
36,598
|
178,265
|
||||||
|
29
|
|
| 31 |
|
|
33
|
|
|
34
|
|
|
35
|
|
|
36
|
|
|
38
|
|
/s/ Deloitte & Touche LLP
|
|
|
San Jose, California
|
|
|
March 28, 2025
|
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$ |
|
$ |
|
||||
|
Restricted cash
|
|
|
||||||
|
Marketable securities
|
|
|
||||||
|
Accounts receivable
|
|
|
||||||
|
Inventory
|
|
|
||||||
|
Prepaid expenses and other current assets
|
|
|
||||||
|
Total current assets
|
|
|
||||||
|
Property and equipment, net
|
|
|
||||||
|
Operating lease right-of-use assets
|
|
|
||||||
|
Intangible assets, net
|
|
|
||||||
|
Goodwill
|
|
|
||||||
|
Other non-current assets
|
|
|
||||||
|
Total assets
|
$ |
|
$ |
|
||||
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$ |
|
$
|
|
||||
|
Accrued and other current liabilities
|
|
|
||||||
|
Operating lease liabilities
|
|
|
||||||
|
Current portion of long-term debt
|
|
|
||||||
|
Total current liabilities
|
|
|
||||||
|
Debt
|
|
|
||||||
|
Operating lease liabilities, non-current
|
|
|
||||||
|
Other non-current liabilities
|
|
|
||||||
|
Total liabilities not subject to compromise
|
|
|
||||||
|
Liabilities subject to compromise
|
|
|
||||||
|
Total liabilities
|
|
|
||||||
|
Commitments and contingencies (see Note 18)
|
||||||||
|
Stockholders’ deficit:
|
||||||||
|
Preferred stock, $
|
|
|
||||||
|
Class A common stock, $
|
|
|
||||||
|
Class B common stock, $
|
|
|
||||||
|
Additional paid-in capital
|
|
|
||||||
|
Accumulated other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
|
Treasury stock, at cost,
|
(
|
)
|
(
|
)
|
||||
|
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
|
Total stockholders’ deficit
|
(
|
)
|
(
|
)
|
||||
|
Total liabilities and stockholders’ deficit
|
$
|
|
$
|
|
||||
|
Year Ended December 31,
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
Revenue:
|
||||||||||||
|
Products
|
$
|
|
$
|
|
$
|
|
||||||
|
Services
|
|
|
|
|||||||||
|
Total revenue
|
|
|
|
|||||||||
|
Cost of sales:
|
||||||||||||
|
Products (includes loss on firm purchase commitments of $
|
|
|
|
|||||||||
|
Services
|
|
|
|
|||||||||
|
Total cost of sales
|
|
|
|
|||||||||
|
Gross loss
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Operating expenses:
|
||||||||||||
|
Research and development
|
|
|
|
|||||||||
|
Sales and marketing
|
|
|
|
|||||||||
|
General and administrative
|
|
|
|
|||||||||
|
Impairment of goodwill and intangible assets
|
|
|
|
|||||||||
|
Impairment of long-lived assets
|
|
|
|
|||||||||
|
Restructuring and other costs
|
|
|
|
|||||||||
|
Total operating expenses
|
|
|
|
|||||||||
|
Loss from operations
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Other income (expense), net:
|
||||||||||||
|
Change in fair value of warrant liabilities
|
|
|
|
|||||||||
|
Interest expense
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Interest income
|
|
|
|
|||||||||
|
Gain on extinguishment of debt
|
|
|
|
|||||||||
|
(Loss) gain from acquisition of EM4
|
(
|
)
|
|
|
||||||||
|
Changes in fair value of derivative liability
|
(
|
)
|
|
|
||||||||
|
Losses and impairments related to investments and certain other assets, and other income (expense)
|
|
(
|
)
|
(
|
)
|
|||||||
|
Total other income (expense), net
|
(
|
)
|
|
(
|
)
|
|||||||
|
Loss before reorganization items and provision for income taxes
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Reorganization items
|
|
|
|
|||||||||
|
Provision for income taxes
|
|
(
|
)
|
|
||||||||
|
Net loss
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Less: Deemed dividend on Series A preferred stock
|
|
|
|
|||||||||
|
Net loss attributable to common stockholders
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Net loss per share attributable to common stockholders:
|
||||||||||||
|
Basic
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Diluted
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Shares used in computing net loss per share:
|
||||||||||||
|
Basic
|
|
|
|
|||||||||
|
Diluted
|
|
|
|
|||||||||
|
Comprehensive Loss:
|
||||||||||||
|
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Net unrealized (losses) gains on available-for-sale debt securities
|
(
|
)
|
(
|
)
|
|
|||||||
|
Comprehensive loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
*
|
All periods presented have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 20, 2024. Refer to Note 1 for further information.
|
|
Series A
Preferred Stock
|
Class A
Common Stock
|
Class B
Common Stock
|
||||||||||||||||||||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Shares
|
Amount
|
Additional
Paid-in
Capital
|
Accumulated
Other
Comprehensive
Income (Loss)
|
Treasury
Stock
|
Accumulated
Deficit
|
Total
Stockholders’
Deficit
|
||||||||||||||||||||||||||||||||||
|
Balance as of December 31, 2022
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||||||||||||||||
|
Issuance of Class A common stock upon exercise of stock options and vesting of restricted stock units
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock under ESPP
|
—
|
—
|
|
|
—
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock under Equity Financing Program
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock to a TPK group company
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock to Plus AI
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Vendor payments under the stock in lieu of cash program
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Milestone awards relating to acquisitions
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Stock-based compensation
|
—
|
—
|
—
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Payments of employee taxes related to stock-based awards
|
—
|
—
|
—
|
|
—
|
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||||||||||||||||||||
|
Other comprehensive loss
|
—
|
—
|
—
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Net loss
|
—
|
—
|
—
|
|
—
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||||||||||||||
|
Balance as of December 31, 2023
|
|
|
|
|
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||||||||||
|
Issuance of Class A common stock upon exercise of stock options and vesting of restricted stock units
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock under ESPP
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock under 401(k) Plan
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock under Equity Financing Program
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock upon conversion of 2030 Convertible Notes
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock in settlement of certain claims
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Vendor payments under the stock in lieu of cash program
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Milestone awards relating to acquisitions
|
—
|
—
|
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Conversion of Class B common stock to Class A common stock
|
—
|
—
|
|
—
|
(
|
)
|
—
|
—
|
—
|
—
|
—
|
—
|
||||||||||||||||||||||||||||||||
|
Expense related to Volvo Warrants
|
—
|
—
|
—
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Stock-based compensation
|
—
|
—
|
—
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Payments of employee taxes related to stock-based awards
|
—
|
—
|
—
|
|
—
|
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||||||||||||||||||||
|
Other comprehensive income
|
—
|
—
|
—
|
|
—
|
|
|
(
|
)
|
|
|
(
|
)
|
|||||||||||||||||||||||||||||||
|
Net loss
|
—
|
—
|
—
|
|
—
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||||||||||||||
|
Balance as of December 31, 2024
|
|
|
|
|
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||||||||||||||||||||||||
|
Issuance of Series A preferred stock, net of issuance costs and discount of $
|
|
|
—
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock as commitment fee
|
—
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock upon conversion of Series A preferred stock
|
(
|
)
|
(
|
)
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||
|
Deemed dividend on Series A preferred stock
|
—
|
|
—
|
|
—
|
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||||||||||||||||||||
|
Issuance of Class A common stock upon vesting of restricted stock units
|
—
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock under ESPP
|
—
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock upon conversion of 2026 Convertible Senior Notes
|
—
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock upon conversion of 2030 Convertible Notes
|
—
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock under the Equity Financing Program
|
—
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Issuance of Class A common stock to a wholly owned subsidiary of TPK
|
—
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Vendor payments under the stock-in-lieu of cash program
|
—
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Expense related to Volvo warrants
|
—
|
|
—
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Share-based compensation, including restructuring costs
|
—
|
|
—
|
|
—
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||
|
Payments of employee taxes related to vested restricted stock units
|
—
|
|
—
|
|
—
|
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||||||||||||||||||||
|
Other comprehensive loss
|
—
|
|
—
|
|
—
|
|
|
(
|
)
|
|
|
(
|
)
|
|||||||||||||||||||||||||||||||
|
Net loss
|
—
|
|
—
|
|
—
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||||||||||||||
|
Balance as of December 31, 2025
|
|
$
|
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||||||||||||||||||||
|
*
|
All periods presented have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 20, 2024. Refer to Note 1 for further information.
|
|
Year Ended December 31,
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
Cash flows from operating activities:
|
||||||||||||
|
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||
|
Depreciation and amortization
|
|
|
|
|||||||||
|
Amortization of operating lease right-of-use assets
|
|
|
|
|||||||||
|
Amortization of discount on marketable securities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Loss on marketable securities
|
|
|
|
|||||||||
|
Losses and impairments on non-marketable securities and certain other assets
|
|
|
|
|||||||||
|
Change in fair value of warrants
|
|
(
|
)
|
(
|
)
|
|||||||
|
Vendor stock in lieu of cash program
|
|
|
|
|||||||||
|
Amortization of debt discount and issuance costs
|
|
|
|
|||||||||
|
Inventory write-offs and write-downs
|
|
|
|
|||||||||
|
Loss on firm purchase commitments
|
|
|
|
|||||||||
|
Change in the fair value of the derivatives
|
|
(
|
)
|
|
||||||||
|
Gain or write-off on sale or disposal of property and equipment
|
|
(
|
)
|
|
||||||||
|
Gain on extinguishment of debt
|
(
|
)
|
(
|
)
|
|
|||||||
|
Share-based compensation, including restructuring costs
|
|
|
|
|||||||||
|
Impairment of goodwill and other intangible assets
|
|
|
|
|||||||||
|
Impairment of long-lived assets
|
|
|
|
|||||||||
|
Loss (gain) from acquisition of EM4
|
|
(
|
)
|
|
||||||||
|
Provision for credit loss
|
|
|
|
|||||||||
|
Gain from sale of investment
|
(
|
)
|
|
|
||||||||
|
Change in product warranty and other
|
|
(
|
)
|
|
||||||||
|
Deferred taxes
|
|
(
|
)
|
(
|
)
|
|||||||
|
Reorganization items
|
|
|
|
|||||||||
|
Changes in operating assets and liabilities:
|
||||||||||||
|
Accounts receivable
|
|
|
(
|
)
|
||||||||
|
Inventories
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Prepaid expenses and other current assets
|
|
(
|
)
|
|
||||||||
|
Other non-current assets
|
|
|
|
|||||||||
|
Accounts payable
|
|
(
|
)
|
|
||||||||
|
Accrued and other current liabilities
|
(
|
)
|
(
|
)
|
|
|||||||
|
Other non-current liabilities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Net cash used in operating activities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Cash flows from investing activities:
|
||||||||||||
|
Purchases of marketable securities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Proceeds from maturities of marketable securities
|
|
|
|
|||||||||
|
Proceeds from sales/redemptions of marketable securities
|
|
|
|
|||||||||
|
Issuance of promissory notes
|
(
|
)
|
|
|
||||||||
|
Proceeds from sales of equity investment
|
|
|
|
|||||||||
|
Purchases of property and equipment
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Acquisition of EM4 (net of cash acquired)
|
|
(
|
)
|
|
||||||||
|
Proceeds from disposal of property and equipment
|
|
|
|
|||||||||
|
Acquisition of Seagate’s lidar business
|
|
|
(
|
)
|
||||||||
|
Net cash provided by investing activities
|
|
|
|
|||||||||
| Year Ended December 31, | ||||||||||||
| 2025 |
2024 |
2023 |
||||||||||
|
Cash flows from financing activities:
|
||||||||||||
|
Net proceeds from issuance of Class A common stock under the Equity Financing Program
|
|
|
|
|||||||||
|
Proceeds from issuance of Senior notes, net of Senior Notes and 2030 Convertible Notes issuance costs
|
|
|
|
|||||||||
|
Proceeds from exercise of stock options
|
|
|
|
|||||||||
|
Proceeds from sale of Class A common stock under ESPP
|
|
|
|
|||||||||
|
Payments of employee taxes related to stock-based awards
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Proceeds from issuance of Class A common stock to a wholly owned subsidiary of TPK
|
|
|
|
|||||||||
|
Proceeds from a financing transaction
|
|
|
|
|||||||||
|
Repurchases of 2026 Convertible Senior Notes
|
(
|
)
|
|
|
||||||||
|
Proceeds from issuance of Series A preferred stock, net of issuance costs, discount and commitment fees
|
|
|
|
|||||||||
|
Net cash provided by financing activities
|
|
|
|
|||||||||
|
Net (decrease) increase in cash, cash equivalents and restricted cash
|
(
|
)
|
(
|
)
|
|
|||||||
|
Beginning cash, cash equivalents and restricted cash
|
|
|
|
|||||||||
|
Ending cash, cash equivalents and restricted cash
|
$
|
|
$
|
|
$
|
|
||||||
|
Supplemental disclosures of cash flow information:
|
||||||||||||
|
Cash paid for interest
|
$
|
|
$
|
|
$
|
|
||||||
|
Supplemental disclosures of noncash investing and financing activities:
|
||||||||||||
|
Conversion of 2030 Convertible Notes
|
|
|
|
|||||||||
|
Conversion of 2026 Convertible Notes
|
|
|
|
|||||||||
|
Conversion of Series A preferred stock to Class A common stock
|
|
|
|
|||||||||
|
Deemed dividend on Series A preferred stock
|
(
|
)
|
|
|
||||||||
|
Recognition/derecognition of right-of-use assets in exchange for lease obligations
|
(
|
)
|
(
|
)
|
|
|||||||
|
Purchases of property and equipment recorded in accounts payable and accrued liabilities
|
|
|
|
|||||||||
|
Vendor stock in lieu of cash program—advances for capital projects and equipment
|
|
|
|
|||||||||
|
Investment in Plus
|
|
|
|
|||||||||
|
Asset Category
|
Estimated useful lives
|
|
|
Machinery and equipment
|
|
|
|
Computer hardware and software
|
|
|
|
Demonstration fleet and demonstration units
|
|
|
|
Leasehold improvements
|
Shorter of useful life or lease term
|
|
|
Vehicles
|
|
|
|
Furniture and fixtures
|
|
| • |
Identifying the contract, or contracts, with the customer;
|
| • |
Identifying the performance obligations in the contract;
|
| • |
Determining the transaction price;
|
| • |
Allocating the transaction price to performance obligations in the contract; and
|
| • |
Recognizing revenue when, or as, the Company satisfies performance obligations by transferring the promised goods or services.
|
|
December 31, 2025
|
||||
|
2030 Convertible Notes (1)
|
$
|
|
||
|
2026 Convertible Senior Notes (1)
|
|
|||
|
Accrued interest
|
|
|||
|
Operating lease liabilities
|
|
|||
|
Accrual for loss on firm purchase commitments
|
|
|||
|
Accounts payables
|
|
|||
|
Total liabilities subject to compromise
|
$
|
|
||
| (1) |
|
|
Year ended
December 31, 2025
|
||||
|
Unamortized debt discounts (1)
|
$ |
|
||
|
Unamortized debt issuance costs (1)
|
|
|||
|
Professional fees
|
|
|||
|
Total reorganization items(2)
|
$
|
|
||
|
(1)
|
Refer to Note 10, “Debt” for additional information.
|
|
(2)
|
|
|
December 31, 2025
|
||||
|
ASSETS
|
||||
|
Current assets:
|
||||
|
Cash and cash equivalents
|
$
|
|
||
|
Restricted cash
|
|
|||
|
Marketable securities
|
|
|||
|
Accounts receivable
|
|
|||
|
Accounts receivable from non-debtor affiliates
|
|
|||
|
Inventory
|
|
|||
|
Prepaid expenses and other current assets
|
|
|||
|
Total current assets
|
|
|||
|
Property and equipment, net
|
|
|||
|
Operating lease right-of-use assets
|
|
|||
|
Intangible assets, net
|
|
|||
|
Goodwill
|
|
|||
|
Investment in non-debtor affiliates
|
|
|||
|
Other non-current assets
|
|
|||
|
Total assets
|
$
|
|
||
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
||||
|
Current liabilities:
|
||||
|
Accounts payable
|
$
|
|
||
|
Accrued and other current liabilities
|
|
|||
|
Current portion of long-term debt
|
|
|||
|
Total current liabilities
|
|
|||
|
Other non-current liabilities
|
|
|||
|
Total liabilities not subject to compromise
|
|
|||
|
Liabilities subject to compromise
|
|
|||
|
Total liabilities
|
|
|||
|
Total stockholders’ deficit
|
(
|
)
|
||
|
Total liabilities and stockholders’ deficit
|
$
|
|
||
|
Year ended
December 31,2025
|
||||
|
Revenue:
|
||||
|
Products
|
$
|
|
||
|
Services
|
|
|||
|
Total revenue
|
|
|||
|
Cost of sales:
|
||||
|
Products
|
|
|||
|
Services
|
|
|||
|
Non-debtor affiliates
|
|
|||
|
Total cost of sales
|
|
|||
|
Gross loss
|
(
|
)
|
||
|
Operating expenses:
|
||||
|
Research and development
|
|
|||
|
Research and development expenses from non-debtor affiliates
|
|
|||
|
Sales and marketing
|
|
|||
|
Sales and marketing expenses from non-debtor affiliates
|
|
|||
|
General and administrative
|
|
|||
|
General and administrative expenses from non-debtor affiliates
|
|
|||
|
Impairment of long-lived assets
|
|
|||
|
Restructuring and other costs
|
|
|||
|
Total operating expenses
|
|
|||
|
Loss from operations
|
(
|
)
|
||
|
Other income (expense), net:
|
||||
|
Interest expense
|
(
|
)
|
||
|
Interest income
|
|
|||
|
Gain on extinguishment of debt
|
|
|||
|
Loss from acquisition of EM4
|
(
|
)
|
||
|
Changes in fair value of derivative liability
|
(
|
)
|
||
|
Losses and impairments related to investments and certain other assets, and other income (expense)
|
(
|
)
|
||
|
Total other income (expense), net
|
(
|
)
|
||
|
Loss before reorganization items and provision for income taxes
|
(
|
)
|
||
|
Reorganization items
|
|
|||
|
Provision for income taxes
|
|
|||
|
Net loss
|
(
|
)
|
||
|
Year Ended
December 31, 2025
|
||||
|
Cash flows from operating activities:
|
||||
|
Net loss
|
$
|
(
|
)
|
|
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||
|
Depreciation and amortization
|
|
|||
|
Amortization of operating lease right-of-use assets
|
|
|||
|
Amortization of discount on marketable securities
|
(
|
)
|
||
|
Loss on marketable securities
|
|
|||
|
Vendor stock in lieu of cash program
|
|
|||
|
Amortization of debt discount and issuance costs
|
|
|||
|
Inventory write-offs and write-downs
|
|
|||
|
Loss on firm purchase commitments
|
|
|||
|
Change in the fair value of the derivatives
|
|
|||
|
Gain or write-off on sale or disposal of property and equipment
|
|
|||
|
Gain on extinguishment of debt
|
(
|
)
|
||
|
Share-based compensation, including restructuring costs
|
|
|||
|
Impairment of long-lived assets
|
|
|||
|
Loss from acquisition of EM4
|
|
|||
|
Provision for credit loss
|
|
|||
|
Gain from sale of investment
|
(
|
)
|
||
|
Change in product warranty and other
|
|
|||
|
Reorganization items
|
|
|||
|
Changes in operating assets and liabilities:
|
||||
|
Accounts receivable
|
|
|||
|
Accounts receivable from non-debtor affiliates
|
(
|
)
|
||
|
Inventories
|
(
|
)
|
||
|
Prepaid expenses and other current assets
|
|
|||
|
Other non-current assets
|
|
|||
|
Accounts payable
|
|
|||
|
Accrued and other current liabilities
|
(
|
)
|
||
|
Other non-current liabilities
|
(
|
)
|
||
|
Net cash used in operating activities
|
(
|
)
|
||
|
Cash flows from investing activities:
|
||||
|
Purchases of marketable securities
|
(
|
)
|
||
|
Proceeds from maturities of marketable securities
|
|
|||
|
Proceeds from sales/redemptions of marketable securities
|
|
|||
|
Issuance of promissory notes
|
(
|
)
|
||
|
Proceeds from sales of equity investment
|
|
|||
|
Purchases of property and equipment
|
(
|
)
|
||
|
Acquisition of EM4 (net of cash acquired)
|
|
|||
|
Proceeds from disposal of property and equipment
|
|
|||
|
Net cash provided by investing activities
|
|
|||
|
Cash flows from financing activities:
|
||||
|
Net proceeds from issuance of Class A common stock under the Equity Financing Program
|
|
|||
|
Proceeds from sale of Class A common stock under ESPP
|
|
|||
|
Payments of employee taxes related to stock-based awards
|
(
|
)
|
||
|
Repurchases of 2026 Convertible Senior Notes
|
(
|
)
|
||
|
Proceeds from issuance of Series A preferred stock, net of issuance costs, discount and commitment fees
|
|
|||
|
Net cash provided by financing activities
|
|
|||
|
Net (decrease) increase in cash, cash equivalents and restricted cash
|
(
|
)
|
||
|
Beginning cash, cash equivalents and restricted cash
|
|
|||
|
Ending cash, cash equivalents and restricted cash
|
$
|
|
||
|
Recorded Value
|
||||
|
Cash and cash equivalents
|
$
|
|
||
|
Accounts receivable
|
|
|||
|
Contract asset
|
|
|||
|
Inventories, net
|
|
|||
|
Prepaid expenses and other current assets
|
|
|||
|
Property plant and equipment
|
|
|||
|
Operating lease right-of-use assets
|
|
|||
|
Total assets acquired
|
|
|||
|
Current liabilities
|
(
|
)
|
||
|
Operating lease liabilities, non-current
|
(
|
)
|
||
|
Total liabilities assumed
|
(
|
)
|
||
|
Net assets acquired
|
$
|
|
||
|
Year Ended December 31,
|
||||||||||||||||||||||||
|
2025
|
2024
|
2023
|
||||||||||||||||||||||
|
Revenue
|
% of Revenue
|
Revenue
|
% of Revenue
|
Revenue
|
% of Revenue
|
|||||||||||||||||||
|
Revenue by primary geographical market:
|
||||||||||||||||||||||||
|
North America
|
$
|
|
|
%
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||||||
|
Asia Pacific
|
|
|
%
|
|
|
%
|
|
|
%
|
|||||||||||||||
|
Europe and Middle East
|
|
|
%
|
|
|
%
|
|
|
%
|
|||||||||||||||
|
Total
|
$
|
|
|
%
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||||||
|
Revenue by timing of recognition:
|
||||||||||||||||||||||||
|
Recognized at a point in time
|
$
|
|
|
%
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||||||
|
Recognized over time
|
|
|
%
|
|
|
%
|
|
|
%
|
|||||||||||||||
|
Total
|
$
|
|
|
%
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||||||
|
Revenue by segment:
|
||||||||||||||||||||||||
|
Autonomy Solutions
|
$
|
|
|
%
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||||||
|
ATS
|
|
|
%
|
|
|
%
|
|
|
%
|
|||||||||||||||
|
Total
|
$
|
|
|
%
|
$
|
|
|
%
|
$
|
|
|
%
|
||||||||||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Contract assets, current
|
$
|
|
$
|
|
||||
|
Contract assets, non-current
|
|
|
||||||
|
Ending balance
|
$
|
|
$
|
|
||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Beginning balance
|
$
|
|
$
|
|
||||
|
Amounts billed that were included in the contract assets beginning balance
|
(
|
)
|
(
|
)
|
||||
|
Contract assets from acquisition of EM4 (See Note 4)
|
|
|
||||||
|
Revenue recognized for performance obligations that have been satisfied but for which amounts have not been billed
|
|
|
||||||
|
Ending balance
|
$
|
|
$
|
|
||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Contract liabilities, current
|
$
|
|
$
|
|
||||
|
Contract liabilities, non-current
|
|
|
||||||
|
Ending balance
|
$
|
|
$
|
|
||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Beginning balance
|
$
|
|
$
|
|
||||
|
Revenue recognized that was included in the contract liabilities beginning balance
|
(
|
)
|
(
|
)
|
||||
|
Increase due to cash received and not recognized as revenue and billings in excess of revenue recognized during the period
|
|
|
||||||
|
Ending balance
|
$
|
|
$
|
|
||||
|
Severance
Expense
|
Other Expense
|
Total
|
||||||||||
|
Balance as of December 31, 2024
|
$
|
|
$
|
|
$
|
|
||||||
|
Restructuring charges
|
|
|
|
|||||||||
|
Cash payments
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Non-cash charges
|
(
|
)
|
|
(
|
)
|
|||||||
|
Balance as of December 31, 2025
|
$
|
|
$
|
|
$
|
|
||||||
|
December 31, 2024
|
||||||||||||||||
|
Cost
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Fair Value
|
|||||||||||||
|
U.S. treasury securities
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Commercial paper
|
|
|
|
|
||||||||||||
|
Corporate bonds
|
|
|
(
|
)
|
|
|||||||||||
|
Certificate of deposits
|
|
|
|
|
||||||||||||
|
Total debt securities
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||
|
Included in cash and cash equivalents
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Included in marketable securities
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||
|
December 31, 2024
|
||||||||
|
Gross
Unrealized
Losses
|
Fair Value
|
|||||||
|
U.S. agency and government sponsored securities
|
$
|
|
$
|
|
||||
|
Corporate bonds
|
(
|
)
|
|
|||||
|
Total
|
$
|
(
|
)
|
$
|
|
|||
|
December 31,
|
|||||||||
| Consolidated Balance Sheets Location | 2025 |
2024 |
|||||||
|
Money market funds (1)
|
Cash and cash equivalents
|
$
|
|
$
|
|
||||
|
Marketable equity investments (1)
|
Marketable securities
|
|
|
||||||
|
Investment in non-marketable securities (2)
|
Other non-current assets
|
|
|
||||||
|
Total
|
$
|
|
$
|
|
|||||
|
(1)
|
|
|
(2)
|
|
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Cash
|
$
|
|
$
|
|
||||
|
Money market funds
|
|
|
||||||
|
U.S. treasury securities
|
|
|
||||||
|
Commercial paper
|
|
|
||||||
|
Corporate bonds
|
|
|
||||||
|
Total cash and cash equivalents
|
$
|
|
$
|
|
||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Raw materials
|
$
|
|
$
|
|
||||
|
Work-in-process
|
|
|
||||||
|
Finished goods
|
|
|
||||||
|
Total inventory
|
$
|
|
$
|
|
||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Prepaid expenses
|
$
|
|
$
|
|
||||
|
Contract assets
|
|
|
||||||
|
Advance payments to vendors
|
|
|
||||||
|
Other receivables
|
|
|
||||||
|
Total prepaid expenses and other current assets
|
$
|
|
$
|
|
||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Machinery and equipment
|
$
|
|
$
|
|
||||
|
Computer hardware and software
|
|
|
||||||
|
Land
|
|
|
||||||
|
Leasehold improvements
|
|
|
||||||
|
Vehicles, including demonstration fleet
|
|
|
||||||
|
Furniture and fixtures
|
|
|
||||||
|
Construction in progress
|
|
|
||||||
|
Total property and equipment
|
|
|
||||||
|
Impairment
|
(
|
)
|
|
|||||
|
Accumulated depreciation and amortization
|
(
|
)
|
(
|
)
|
||||
|
Total property and equipment, net
|
$
|
|
$
|
|
||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Beginning of the period
|
$
|
|
$
|
|
||||
|
Additions
|
|
|
||||||
|
Amortization
|
(
|
)
|
(
|
)
|
||||
|
(1)
|
(
|
)
|
(
|
)
|
||||
|
End of the period
|
$
|
|
$
|
|
||||
|
December 31, 2025
|
December 31, 2024
|
|||||||||||||||||||||||||||||||||||||||
|
Gross
Carrying
Amount
|
Accumulated
Amortization
|
Impairment
(1)
|
Net
Carrying
Amount
|
Weighted
Average
Remaining
Period
(Years)
|
Gross
Carrying
Amount
|
Accumulated
Amortization
|
Impairment
|
Net
Carrying
Amount
|
Weighted
Average
Remaining
Period
(Years)
|
|||||||||||||||||||||||||||||||
|
Customer relationships
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|
$
|
|
$
|
(
|
)
|
$
|
|
$
|
|
|
|||||||||||||||||||
|
Customer backlog
|
|
(
|
)
|
|
|
—
|
|
(
|
)
|
|
|
—
|
||||||||||||||||||||||||||||
|
Tradename
|
|
(
|
)
|
|
|
|
|
(
|
)
|
|
|
|
||||||||||||||||||||||||||||
|
Assembled workforce
|
|
(
|
)
|
|
|
—
|
|
(
|
)
|
|
|
—
|
||||||||||||||||||||||||||||
|
Developed technology
|
|
(
|
)
|
(
|
)
|
|
|
|
(
|
)
|
|
|
|
|||||||||||||||||||||||||||
|
IPR&D
|
|
|
(
|
)
|
|
—
|
|
|
(
|
)
|
|
—
|
||||||||||||||||||||||||||||
|
Total intangible assets
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
|
||||||||||||||||||
| (1) |
|
|
Period
|
Expected Future
Amortization Expense
|
|||
|
2026
|
$
|
|
||
|
2027
|
|
|||
|
2028
|
|
|||
|
2029
|
|
|||
|
2030
|
|
|||
|
Thereafter
|
|
|||
|
Total
|
$
|
|
||
|
Autonomy
Solutions
|
ATS
|
Total
|
||||||||||
|
Balance as of December 31, 2023
|
$
|
|
$
|
|
$
|
|
||||||
|
related to Freedom Photonics
|
|
(
|
)
|
(
|
)
|
|||||||
|
Balance as of December 31, 2024
|
$
|
|
$
|
|
$
|
|
||||||
|
related to Optogration
|
|
(
|
)
|
(
|
)
|
|||||||
|
Balance as of December 31, 2025
|
$
|
|
$
|
|
$
|
|
||||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Security deposits
|
$
|
|
$
|
|
||||
|
Non-marketable equity investment (see Note 7 for additional information)
|
|
|
||||||
|
Prepaid expenses non-current
|
|
|
||||||
|
Other non-current assets
|
|
|
||||||
|
Total other non-current assets
|
$
|
|
$
|
|
||||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Accrued compensation and benefits
|
$
|
|
$
|
|
||||
|
Accrued expenses
|
|
|
||||||
|
Warranty reserves
|
|
|
||||||
|
Contract liabilities
|
|
|
||||||
|
Accrued interest payable and other liabilities
|
|
|
||||||
|
Total accrued and other current liabilities
|
$
|
|
$
|
|
||||
|
December 31, 2025
|
December 31, 2024
|
|||||||
|
Beginning of the period
|
$
|
|
$
|
|
||||
|
Provision for credit loss
|
|
|
||||||
|
Write-offs
|
(
|
)
|
|
|||||
|
End of the period
|
$
|
|
$
|
|
||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
|
Principal
|
$
|
|
$
|
|
||||
|
Unamortized debt discount and issuance costs
|
|
(
|
)
|
|||||
|
Net carrying amount
|
$
|
|
$
|
|
||||
|
Year Ended December 31
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
Contractual interest expense
|
$
|
|
$
|
|
$
|
|
||||||
|
Amortization of debt discount and issuance costs
|
|
|
|
|||||||||
|
Total interest expense
|
$
|
|
$
|
|
$
|
|
||||||
|
December 31, 2025
|
||||
|
Principal
|
$
|
|
||
|
Unamortized debt discount and issuance costs
|
|
|||
|
Net carrying amount
|
$
|
|
||
|
Senior Notes
|
||||
|
Derivative liability, as of December 31, 2024
|
$
|
|
||
|
Change in fair value
|
||||
|
Derivative liability, end of period
|
$
|
|||
|
Series 1 Notes
|
Series 2 Notes
|
|||||||
|
Principal
|
$
|
|
$
|
|
||||
|
Unamortized debt discount and issuance costs
|
|
|
||||||
|
Net carrying amount
|
$
|
|
$
|
|
||||
|
Series 1 Notes
|
Series 2 Notes
|
|||||||
|
Derivative liability, as of December 31, 2024
|
$
|
|
$
|
|
||||
|
Change in fair value
|
(
|
)
|
(
|
)
|
||||
|
Decrease of derivative liability upon exercise of conversion option
|
|
(
|
)
|
|||||
|
Derivative liability, end of period
|
$
|
|
$
|
|
||||
|
Series 1 Notes
|
Series 2 Notes
|
|||||||
|
Conversion price
|
$
|
|
$
|
|
||||
|
Risk-free rate
|
|
%
|
|
%
|
||||
|
Effective borrowing rate
|
|
%
|
|
%
|
||||
|
Volatility
|
|
%
|
|
%
|
||||
|
Stock price
|
$
|
|
$
|
|
||||
|
Payment interest rate
|
|
%
|
|
%
|
||||
|
Redemption price
|
$
|
|
$
|
|
||||
|
Fair Value Measured as of
December 31, 2025:
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
|
Assets:
|
||||||||||||||||
|
Cash equivalents:
|
||||||||||||||||
|
Money market funds
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Total cash equivalents
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Marketable investments:
|
||||||||||||||||
|
Marketable equity investments
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Total marketable investments
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Liabilities:
|
||||||||||||||||
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||
|
Total derivative liabilities
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||
|
Fair Value Measured as of
December 31, 2024:
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
|
Assets:
|
||||||||||||||||
|
Cash equivalents:
|
||||||||||||||||
|
Money market funds
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
U.S. treasury securities
|
|
|
|
|
||||||||||||
|
Commercial paper
|
|
|
|
|
||||||||||||
|
Corporate bonds
|
|
|
|
|
||||||||||||
|
Total cash equivalents
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Marketable investments:
|
||||||||||||||||
|
U.S. treasury securities
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Certificate of deposits
|
|
|
|
|
||||||||||||
|
Commercial paper
|
|
|
|
|
||||||||||||
|
Corporate bonds
|
|
|
|
|
||||||||||||
|
Marketable equity investments
|
|
|
|
|
||||||||||||
|
Total marketable investments
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Liabilities:
|
||||||||||||||||
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||
|
Total derivative liabilities
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
||||||
|
December 31,
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
Numerator:
|
||||||||||||
|
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Less: Deemed dividend on Series A preferred stock
|
(
|
)
|
|
|
||||||||
|
Net loss attributable to common stockholders
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Denominator:
|
||||||||||||
|
Weighted average Common shares outstanding—Basic
|
|
|
|
|||||||||
|
Weighted average Common shares outstanding—Diluted
|
|
|
|
|||||||||
|
Net loss per share
|
||||||||||||
|
Basic
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Diluted
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
December 31,
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
Warrants
|
|
|
|
|||||||||
|
Stock-based awards—Equity classified
|
|
|
|
|||||||||
|
Stock-based awards—Liability classified
|
|
|
|
|||||||||
|
Vendor stock-in-lieu of cash program
|
|
|
|
|||||||||
|
Series 1 Notes
|
|
|
|
|||||||||
|
Series 2 Notes
|
|
|
|
|||||||||
|
2026 Convertible Senior Notes
|
|
|
|
|||||||||
|
Earn-out shares
|
|
|
|
|||||||||
|
Total
|
|
|
|
|||||||||
|
Number of
Stock Options
|
Weighted-
Average
Exercise
Price
|
Weighted-
Average
Remaining
Contractual
Life (Years)
|
Aggregate
Intrinsic Value
|
|||||||||||||
|
Outstanding as of December 31, 2024
|
|
$
|
|
|||||||||||||
|
Granted
|
|
|
||||||||||||||
|
Exercised
|
|
|
||||||||||||||
|
Cancelled/Forfeited
|
(
|
)
|
|
|||||||||||||
|
Outstanding as of December 31, 2025
|
|
|
|
$
|
|
|||||||||||
|
Vested and exercisable as of December 31, 2025
|
|
|
|
|
||||||||||||
|
Vested and expected to vest as of December 31, 2025
|
|
|
|
|
||||||||||||
|
Time-Based RSUs
|
Performance-Based and Other RSUs
|
|||||||||||||||
|
Shares
|
Weighted Average
Grant Date Fair
Value per Share
|
Shares
|
Weighted Average
Grant Date Fair
Value per Share
|
|||||||||||||
|
Outstanding as of December 31, 2024
|
|
$
|
|
|
$
|
|
||||||||||
|
Granted
|
|
|
|
|
||||||||||||
|
Forfeited
|
(
|
)
|
|
(
|
)
|
|
||||||||||
|
Vested
|
(
|
)
|
|
|
|
|||||||||||
|
Outstanding as of December 31, 2025
|
|
|
|
|
||||||||||||
| • |
Market condition: Achievement of three stock price milestones: $
|
| • |
Service condition: Approximately
|
| • |
Performance condition: Start of production for at least one series production program.
|
|
Shares
|
Weighted Average
Grant Date Fair
Value per Share
|
|||||||
|
Outstanding as of December 31, 2024
|
|
$
|
|
|||||
|
Granted
|
|
|
||||||
|
Forfeited
|
(
|
)
|
|
|||||
|
Change in units based on performance
|
(
|
)
|
|
|||||
|
Vested
|
|
|
||||||
|
Outstanding as of December 31, 2025
|
|
|
||||||
|
Year Ended December 31,
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
Cost of sales
|
$
|
|
$
|
|
$
|
|
||||||
|
Research and development
|
|
|
|
|||||||||
|
Sales and marketing
|
|
|
|
|||||||||
|
General and administrative
|
(
|
)
|
|
|
||||||||
|
Stock-based compensation related to restructuring
|
(
|
)
|
|
|
||||||||
|
Total
|
$
|
|
$
|
|
$
|
|
||||||
|
Year Ended December 31,
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
Equity Classified Awards:
|
||||||||||||
|
Stock options
|
$
|
|
$
|
|
$
|
|
||||||
|
RSAs
|
|
|
|
|||||||||
|
RSUs
|
|
|
|
|||||||||
|
Management awards
|
(
|
)
|
|
|
||||||||
|
ESPP
|
|
|
|
|||||||||
|
Stock-based compensation related to restructuring
|
(
|
)
|
|
|
||||||||
|
Liability Classified Awards:
|
||||||||||||
|
Equity-settled fixed value
|
|
|
|
|||||||||
|
Optogration
|
|
|
|
|||||||||
|
Freedom Photonics
|
(
|
)
|
|
|
||||||||
|
Other
|
(
|
)
|
|
|
||||||||
|
Total
|
$
|
|
$
|
|
$
|
|
||||||
|
Year Ended December 31,
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
Operating lease cost
|
$
|
|
$
|
|
$
|
|
||||||
|
Variable lease cost
|
|
|
|
|||||||||
|
Total operating lease cost
|
$
|
|
$
|
|
$
|
|
||||||
|
Year Ended December 31,
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
Cash paid for amounts included in the measurement of lease liabilities:
|
||||||||||||
|
Cash paid for operating leases included in operating activities
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Recognition/derecognition of right-of-use asset in exchange for lease obligations:
|
||||||||||||
|
Operating leases
|
(
|
)
|
(
|
)
|
|
|||||||
|
December 31, 2025
|
December 31, 2024
|
|||||||
|
Operating leases:
|
||||||||
|
Operating lease right-of-use assets
|
$
|
|
$
|
|
||||
|
Operating lease liabilities:
|
||||||||
|
Operating lease liabilities, current
|
$
|
|
$
|
|
||||
|
Operating lease liabilities, non-current
|
|
|
||||||
|
Total operating lease liabilities
|
$
|
|
$
|
|
||||
|
December 31, 2025
|
December 31, 2024
|
|||||||
|
Weighted average remaining lease term
|
||||||||
|
Operating leases
|
|
|
||||||
|
December 31, 2025
|
December 31, 2024
|
|||||||
|
Weighted average discount rate
|
||||||||
|
Operating leases
|
|
%
|
|
%
|
||||
|
Year Ending December 31,
|
Operating Leases
|
|||
|
2026
|
$
|
|
||
|
2027
|
|
|||
|
2028
|
|
|||
|
2029
|
|
|||
|
2030
|
|
|||
|
Thereafter
|
|
|||
|
Total lease payments
|
|
|||
|
Less: imputed interest
|
(
|
)
|
||
|
Total leases liabilities (1)
|
$
|
|
||
|
Year Ended December 31,
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
United States
|
$ |
(
|
)
|
$ |
(
|
)
|
$ |
(
|
)
|
|||
|
International
|
|
|
|
|||||||||
|
Loss before provision for (benefit from) income taxes
|
$ |
(
|
)
|
$ |
(
|
)
|
$ |
(
|
)
|
|||
|
Year Ended December 31,
|
||||||||||||
|
2025
|
2024
|
2023
|
||||||||||
|
Current:
|
||||||||||||
|
U.S. federal
|
$
|
|
$
|
|
$
|
(
|
)
|
|||||
|
U.S. state
|
|
|
(
|
)
|
||||||||
|
Foreign
|
|
(
|
)
|
|
||||||||
|
Total current:
|
|
(
|
)
|
|
||||||||
|
Deferred:
|
— |
|||||||||||
|
U.S. federal
|
|
(
|
)
|
(
|
)
|
|||||||
|
U.S. state
|
|
(
|
)
|
(
|
)
|
|||||||
|
Total deferred:
|
|
(
|
)
|
(
|
)
|
|||||||
|
Total provision for (benefit from) income taxes
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
|
Year Ended December 31,
|
||||||||
|
2024
|
2023
|
|||||||
|
U.S. federal provision at statutory rate
|
|
%
|
|
%
|
||||
|
State income taxes
|
|
|
||||||
|
Foreign taxes
|
|
(
|
)
|
|||||
|
Tax credits
|
|
|
||||||
|
Fair value of financial instruments
|
|
|
||||||
|
Stock-based compensation expense
|
(
|
)
|
(
|
)
|
||||
|
Executive compensation
|
(
|
)
|
(
|
)
|
||||
|
Other permanent items
|
|
(
|
)
|
|||||
|
Unrecognized tax benefits
|
|
|
||||||
|
Change in valuation allowance
|
(
|
)
|
(
|
)
|
||||
|
Effective tax rate
|
|
%
|
(
|
%)
|
||||
|
Year ended December 31, 2025
|
||||||||
|
Amount
|
Percentage
|
|||||||
|
Income taxes (benefit) at statutory federal rate
|
(
|
)
|
|
%
|
||||
|
State and local taxes, net of federal income tax effect (1)
|
|
|
%
|
|||||
|
Foreign tax effects:
|
||||||||
|
Other Foreign
|
(
|
)
|
|
%
|
||||
|
Effect of cross-border tax laws:
|
||||||||
|
Global intangible low-taxed income
|
|
(
|
)%
|
|||||
|
Tax credits:
|
||||||||
|
R&D Credit
|
(
|
)
|
|
%
|
||||
|
Changes in valuation allowance (2)
|
|
(
|
)%
|
|||||
|
Nontaxable or nondeductible items:
|
||||||||
|
Excess Tax (Benefit) or Deficit on Stock Awards
|
|
(
|
)%
|
|||||
|
Deferred Compensation FV Adjustment
|
(
|
)
|
|
%
|
||||
|
Other Nontaxable or Nondeductible Items
|
|
(
|
)%
|
|||||
|
Changes in unrecognized tax benefits
|
|
(
|
)%
|
|||||
|
Other Adjustments:
|
||||||||
|
Other Adjustments
|
(
|
)
|
|
%
|
||||
|
Provision / (benefit) for income taxes
|
|
(
|
)%
|
|||||
|
(1)
|
|
(2)
|
|
|
Year Ended December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Deferred tax assets:
|
||||||||
|
Net operating loss carry forward
|
$
|
|
$
|
|
||||
| Capital Loss |
||||||||
|
Tax credits
|
|
|
||||||
|
Accruals and reserves
|
|
|
||||||
|
Stock-based compensation expense
|
|
|
||||||
|
Lease liability (ASC 842)
|
|
|
||||||
|
Section 174 R&D capitalization
|
|
|
||||||
|
Inventory reserves
|
|
|
||||||
|
Depreciation and amortization
|
|
|
||||||
|
Basis difference on debt obligation
|
|
|
||||||
|
Deferred interest expense
|
|
|
||||||
|
Unrealized Gain
|
|
|
||||||
|
Other
|
|
|
||||||
|
Total deferred tax assets
|
|
|
||||||
|
Valuation allowance
|
(
|
)
|
(
|
)
|
||||
|
Total deferred tax asset
|
|
|
||||||
|
Deferred tax liabilities:
|
||||||||
|
Other
|
|
|
||||||
|
ROU asset (ASC 842)
|
|
|
||||||
|
Total deferred tax liabilities
|
|
|
||||||
|
Net deferred tax assets (liabilities)
|
$
|
|
$
|
|
||||
|
|
Year ended
December 31, 2025
|
|||
|
Federal
|
$
|
|
||
|
State
|
|
|||
| Massachusetts |
||||
| New Jersey |
||||
| Other states |
||||
|
Foreign:
|
||||
|
Israel
|
|
|||
|
India
|
|
|||
|
Germany
|
|
|||
|
Other Foreign
|
|
|||
|
Total
|
$
|
|
||
|
December 31,
|
||||||||
|
2025
|
2024
|
|||||||
|
Beginning at December 31, 2024
|
$
|
|
$
|
|
||||
|
Prior Year Additions
|
|
|
||||||
|
Reversal of Prior Year Positions
|
(
|
)
|
(
|
)
|
||||
|
Current Year Additions
|
|
|
||||||
|
Ending Balance at December 31, 2025
|
$
|
|
$
|
|
||||
|
Year ended December 31, 2025
|
||||||||||||
|
Autonomy
Solutions
|
ATS
|
Total
|
||||||||||
|
Revenue:
|
||||||||||||
|
Products
|
$
|
|
$
|
|
$
|
|
||||||
|
Services
|
|
|
|
|||||||||
|
Intersegment revenue
|
|
|
|
|||||||||
|
|
|
|
||||||||||
|
Reconciliation of revenue
|
||||||||||||
|
Elimination of intersegment revenue
|
(
|
)
|
||||||||||
|
Total revenue
|
|
|||||||||||
|
Less:
|
||||||||||||
|
Depreciation and amortization
|
|
|
||||||||||
|
Impairment of goodwill and intangible assets
|
|
|
||||||||||
|
Impairment of long-lived assets
|
|
|
||||||||||
|
Other segment items (a)
|
|
|
||||||||||
|
Operating loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Reconciliation of profit or loss
|
||||||||||||
|
Other income (expense), net
|
(
|
)
|
||||||||||
|
Loss before reorganization items and provision for income taxes
|
$
|
(
|
)
|
|||||||||
|
Other significant items:
|
||||||||||||
|
Total assets
|
$
|
|
$
|
|
$
|
|
||||||
|
Inventory
|
$
|
|
$
|
|
$
|
|
||||||
| • |
Autonomy Solutions - Professional and contracting service expenses, travel expenses, insurance and maintenance expenses, utility expenses, restructuring costs and certain overhead expenses.
|
| • |
ATS - Professional and contracting service expenses, courier & postage expenses, insurance expenses, facility maintenance & utility expenses, restructuring costs and certain overhead
expenses.
|
|
Year ended December 31, 2024
|
||||||||||||
|
Autonomy
Solutions
|
ATS
|
Total
|
||||||||||
|
Revenue:
|
||||||||||||
|
Products
|
$
|
|
$
|
|
$
|
|
||||||
|
Services
|
|
|
|
|||||||||
|
Intersegment revenue
|
|
|
|
|||||||||
|
|
|
|
||||||||||
|
Reconciliation of revenue
|
||||||||||||
|
Elimination of intersegment revenue
|
(
|
)
|
||||||||||
|
Total revenue
|
|
|||||||||||
|
Less:
|
||||||||||||
|
Depreciation and amortization
|
|
|
||||||||||
|
Impairment of goodwill and intangible assets
|
|
|
||||||||||
|
Other segment items (a)
|
|
|
||||||||||
|
Operating loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Reconciliation of profit or loss
|
||||||||||||
|
Other income (expense), net
|
|
|||||||||||
|
Loss before provision for income taxes
|
$
|
(
|
)
|
|||||||||
|
Other significant items:
|
||||||||||||
|
Total assets
|
$
|
|
$
|
|
$
|
|
||||||
|
Inventory
|
$
|
|
$
|
|
$
|
|
||||||
| • |
Autonomy Solutions - Professional and contracting service expenses, travel expenses, insurance and maintenance expenses, utility expenses, restructuring costs and certain overhead expenses.
|
| • |
ATS - Professional and contracting service expenses, courier & postage expenses, insurance expenses, facility maintenance & utility expenses, restructuring costs and certain overhead
expenses.
|
|
Year ended December 31, 2023
|
||||||||||||
|
Autonomy
Solutions
|
ATS
|
Total
|
||||||||||
|
Revenue:
|
||||||||||||
|
Products
|
$
|
|
$
|
|
$
|
|
||||||
|
Services
|
|
|
|
|||||||||
|
Intersegment revenue
|
|
|
|
|||||||||
|
|
|
|
||||||||||
|
Reconciliation of revenue
|
||||||||||||
|
Elimination of intersegment revenue
|
(
|
)
|
||||||||||
|
Total revenue
|
|
|||||||||||
|
Less:
|
||||||||||||
|
Depreciation and amortization
|
|
|
||||||||||
|
Impairment of goodwill and intangible assets
|
|
|
||||||||||
|
Other segment items (a)
|
|
|
||||||||||
|
Operating loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
|
Reconciliation of profit or loss
|
||||||||||||
|
Other income (expense), net
|
(
|
)
|
||||||||||
|
Loss before provision for income taxes
|
$
|
(
|
)
|
|||||||||
|
Other significant items:
|
||||||||||||
|
Total assets
|
$
|
|
$
|
|
$
|
|
||||||
|
Inventory
|
$
|
|
$
|
|
$
|
|
||||||
| • |
Autonomy Solutions - Professional and contracting service expenses, travel expenses, insurance and maintenance expenses, utility expenses, restructuring costs and certain overhead expenses.
|
| • |
ATS - Professional and contracting service expenses, courier & postage expenses, insurance expenses, facility maintenance & utility expenses, restructuring costs and certain overhead
expenses.
|
|
Name
|
Year
|
Salary($)(1)
|
Bonus($)(2)
|
Stock
Awards
($)(3)
|
All Other
Compensation($)(4)
|
Total ($)
|
||||||||||||||||||
|
Paul Ricci
Chief Executive Officer
|
2025
|
355,385
|
850,000
|
4,280,034
|
—
|
7,168,898
|
||||||||||||||||||
|
—
|
—
|
—
|
—
|
—
|
—
|
|||||||||||||||||||
|
Thomas Beaudoin
Chief Financial Officer
|
2025
|
49,231
|
400,000
|
—
|
—
|
449,231
|
||||||||||||||||||
|
—
|
—
|
—
|
—
|
—
|
—
|
|||||||||||||||||||
|
Austin Russell
Former Chief Executive Officer(5)
|
2025
|
—
|
—
|
186,575
|
91,594
|
|
—
|
|||||||||||||||||
|
2024
|
—
|
—
|
—
|
497,253
|
497,253
|
|||||||||||||||||||
|
Thomas J. Fennimore
Former Chief Financial Officer(6)
|
2025
|
276,923
|
1,350,000
|
178,023
|
—
|
1,575,933
|
||||||||||||||||||
|
2024
|
300,000
|
3,125,100
|
1,499,996
|
—
|
4,925,096
|
|||||||||||||||||||
| (1) |
Amounts reflect salary earned during the applicable calendar year.
|
| (2) |
For Messrs. Ricci and Beaudoin, amounts reflect lump sum retention cash bonuses paid in 2025. For more information, please see “Executive Retention Agreement with Messrs. Ricci and Beaudoin” below. For Mr.
Fennimore, the amount in this column reflects quarterly bonus amounts equal to $300,000 and $1,050,000 paid in cash in lieu of the Fixed Value Equity Grant that Mr. Fennimore would otherwise be entitled to.
|
| (3) |
The amounts reported in this column reflect the aggregate grant date fair value for financial statement reporting purposes of restricted stock
units (“RSUs”) and performance-based restricted stock units (“PRSUs”) granted in the applicable fiscal year as determined in accordance with FASB ASC Topic 718. These amounts reflect our accounting expense for these stock awards and do
not represent the actual economic value that may be realized by each named executive officer. The amounts reported for Mr. Russell in this column reflect RSUs granted in connection with Mr. Russell’s
service as a director. In connection with the Company’s Chapter 11 cases filed on December 15, 2025, and pursuant to the terms of the Third Amended Plan, all of the Company’s equity will be canceled, and these amounts may never be
realized. For information on the assumptions used in valuing these awards, refer to Note 15 to the consolidated financial statements included in this Annual Report on Form 10-K.
|
| (4) |
The amounts for Mr. Russell in 2025 reflect Mr. Russell’s director fees. The amounts for Mr. Russell in 2024 represent the incremental cost to the Company of certain personal security measures considered
perquisites. For more information, please see “Perquisites and Other Benefits” below.
|
| (5) |
Mr. Russell resigned as President and Chief Executive Officer of the Company and as Chairperson of the Board, effective May 14, 2025. He did not receive any
compensation for his role as President, Chief Executive Officer and Chairperson. This table does not include any director fees from 2025. Please see “Director Compensation” below.
|
| (6) |
Mr. Fennimore resigned as Chief Financial Officer of the Company, effective November 13, 2025.
|
|
Option Awards
|
Stock Awards
|
|||||||||||||||||||||||||||||||||||
|
Name
|
Grant Date
|
Number of
Securities
Underlying Unexercised Options (#) Exercisable |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
Option
Exercise Price ($) |
Option
Expiration Date |
Number of
Shares Awarded That Have Not Vested (#) |
Market Value
of Shares Awarded That Have Not Vested ($)(1) |
Equity Incentive
Plan Awards:
Number of
Shares, Units of
Stock, or Other
Rights That Have
Not Vested (#)(2)
|
Equity Incentive
Plan Awards:
Market Value or
Payout Value of
unearned
Shares, Units or
Other Rights
That Have Not
Vested ($)
|
|||||||||||||||||||||||||||
|
Paul Ricci
|
7/28/2025
|
—
|
—
|
—
|
—
|
—
|
—
|
273,459
|
21,877
|
|||||||||||||||||||||||||||
|
7/28/2025
|
—
|
—
|
—
|
—
|
—
|
—
|
273,460
|
21,877
|
||||||||||||||||||||||||||||
|
7/28/2025
|
—
|
—
|
—
|
—
|
—
|
—
|
273,460
|
21,877
|
||||||||||||||||||||||||||||
|
7/28/2025
|
—
|
—
|
—
|
—
|
683,650
|
54,692
|
—
|
—
|
||||||||||||||||||||||||||||
|
Thomas
Beaudoin
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|||||||||||||||||||||||||||
|
Austin
Russell(3)
|
5/2/2022
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|||||||||||||||||||||||||||
|
7/3/2025
|
—
|
—
|
—
|
—
|
61,576
|
4,926
|
—
|
—
|
||||||||||||||||||||||||||||
|
Thomas J.
Fennimore
|
5/14/2020
|
122,678
|
—
|
25.05
|
5/13/2030
|
—
|
—
|
—
|
—
|
|||||||||||||||||||||||||||
|
(1)
|
Market values are based on the closing price of our common stock on the OTC market on December 31, 2025 ($0.08).
|
|
(2)
|
Represents PRSU awards which are eligible to vest, if at all, only upon the achievement of certain milestones.
|
|
(3)
|
Mr. Russell’s stock awards for 2025 reflect Mr. Russell’s RSU grant in connection with his service as a director.
|
|
Name
|
Fees Earned or
Paid in Cash
($)
|
Stock Awards
($) (2)(3)
|
Total
($)
|
|||||||||
|
Alec Gores
|
97,292
|
186,575
|
283,867
|
|||||||||
|
Matthew J. Simoncini
|
159,980
|
186,575
|
346,555
|
|||||||||
|
Elizabeth Abrams (1)
|
118,333
|
-
|
118,333
|
|||||||||
|
Patricia Ferrari (1)
|
81,668
|
-
|
81,668
|
|||||||||
|
Mary Lou Jepsen, PhD
|
115,625
|
186,575
|
302,200
|
|||||||||
|
Katharine A. Martin
|
120,208
|
186,575
|
306,783
|
|||||||||
|
Shaun Maguire, PhD
|
92,557
|
186,575
|
279,132
|
|||||||||
|
Dominick Schiano
|
131,723
|
186,575
|
318,298
|
|||||||||
|
Daniel D. Tempesta
|
126,619
|
186,575
|
313,194
|
|||||||||
|
Name
|
Stock Options
|
RR RSUs
|
||||||
|
Alec Gores
|
-
|
61,576
|
||||||
|
Matthew J. Simoncini
|
22,718
|
61,576
|
||||||
|
Elizabeth Abrams
|
-
|
0
|
||||||
|
Patricia Ferrari
|
-
|
0
|
||||||
|
Mary Lou Jepsen, PhD
|
-
|
61,576
|
||||||
|
Katharine A. Martin
|
-
|
61,576
|
||||||
|
Shaun Maguire, PhD
|
-
|
61,576
|
||||||
|
Dominick Schiano
|
-
|
82,186
|
||||||
|
Daniel D. Tempesta
|
-
|
61,576
|
||||||
| • |
each stockholder known by us to be the beneficial owner of more than 5% of our Class A common stock or Class B common stock;
|
| • |
each of our directors and director nominees in this Amendment;
|
| • |
each of our named executive officers; and
|
| • |
all of our directors and executive officers as a group.
|
|
Class A
|
Class B
|
|||||||||||||||||||
|
Name and Address of Beneficial Owners
|
Number of Shares
|
%
|
Number of Shares
|
%
|
% of Total Voting Power**
|
|||||||||||||||
|
Current Directors, Nominees and Named Executive Officers
|
||||||||||||||||||||
|
Paul Ricci
|
605,517
|
*
|
-
|
-
|
*
|
|||||||||||||||
|
Thomas Beaudoin
|
-
|
|||||||||||||||||||
|
Elizabeth Abrams
|
-
|
*
|
-
|
-
|
*
|
|||||||||||||||
|
Alec Gores
|
347,732
|
*
|
-
|
-
|
*
|
|||||||||||||||
|
Patricia Ferrari
|
-
|
|||||||||||||||||||
|
Mary Lou Jepsen, PhD
|
14,932
|
*
|
-
|
-
|
*
|
|||||||||||||||
|
Shaun Maguire, PhD
|
14,213
|
*
|
-
|
-
|
*
|
|||||||||||||||
|
Katharine A. Martin
|
15,055
|
*
|
-
|
-
|
*
|
|||||||||||||||
|
Austin Russell
|
-
|
*
|
4,872,578
|
100
|
%
|
39.8
|
%
|
|||||||||||||
|
Dominick Schiano
|
10,571
|
*
|
-
|
-
|
*
|
|||||||||||||||
|
Matthew J. Simoncini
|
39,239
|
*
|
-
|
-
|
*
|
|||||||||||||||
|
Daniel D. Tempesta
|
18,860
|
*
|
-
|
-
|
*
|
|||||||||||||||
|
Thomas J. Fennimore(1)
|
255,015
|
*
|
-
|
-
|
*
|
|||||||||||||||
|
All Directors and Executive Officers as a Group (12 Individuals)
|
1,066,119
|
1.4
|
%
|
4,872,578
|
100
|
%
|
40.7
|
%
|
||||||||||||
|
Plan category
|
Number of
securities to be issued upon exercise of outstanding options, warrants and vesting of RSAs and RSUs |
Weighted-average
exercise price of outstanding options and warrants |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
|||||||||
|
(a)
|
(b)
|
(c)
|
||||||||||
|
Equity compensation plans approved by security holders
|
2,753,087
|
$
|
22
|
(1)
|
3,758,999
|
|||||||
|
Equity compensation plans not approved by security holders
|
—
|
(1)
|
—
|
—
|
||||||||
|
Total
|
2,753,087
|
3,758,999
|
||||||||||
| • |
we, have been or are to be a participant;
|
| • |
the amounts involved exceeded or exceeds $120,000; and
|
| • |
any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or
entities, had or will have a direct or indirect material interest.
|
|
|
Year Ended December 31, 2025
|
|||||||
|
|
2025
|
2024
|
||||||
|
Audit Fees(1)
|
$
|
1,144
|
$
|
2,122
|
||||
|
Audit-Related Fees(2)
|
-
|
454
|
||||||
|
Tax Fees
|
-
|
9
|
||||||
|
All Other Fees(3)
|
-
|
2
|
||||||
|
Total
|
$
|
1,144
|
$
|
2,587
|
||||
| 1. |
Financial Statements. The financial statements included in “Index to the Consolidated Financial Statements” in Part II, Item 8 are filed as part of this Form 10-K.
|
| 2. |
Financial Statement Schedules. None.
|
| 3. |
Exhibits. Exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Form 10-K.
|
|
|
Incorporation by Reference
|
||||||||||||||
|
Exhibit
Number
|
Description
|
|
Form
|
|
File Number
|
Exhibit/Ap
pendix
Reference
|
Filing
Date
|
Filed
Herewith
|
|||||||
|
2.1+
|
8-K/A
|
001-38791
|
10.1
|
12/15/25
|
|||||||||||
|
2.2+
|
8-K
|
001-38791
|
10.1
|
01/28/26
|
|||||||||||
|
3.1
|
8-K/A
|
001-38791
|
3.1
|
12/8/20
|
|||||||||||
|
3.2
|
10-K
|
001-38791
|
3.2
|
02/28/24
|
|||||||||||
|
3.3
|
8-K
|
001-38791
|
3.1
|
11/22/24
|
|||||||||||
|
3.4
|
8-K
|
001-38791
|
3.1
|
08/30/24
|
|||||||||||
|
3.5
|
8-K
|
001-38791
|
3.1
|
05/22/25
|
|||||||||||
|
4.1
|
8-K/A
|
001-38791
|
4.1
|
12/8/20
|
|||||||||||
|
4.2
|
8-K/A
|
001-38791
|
4.2
|
12/8/20
|
|||||||||||
|
4.3
|
8-K/A
|
001-38791
|
4.3
|
12/8/20
|
|||||||||||
|
4.4
|
10-K
|
001-38791
|
4.4
|
03/28/25
|
|||||||||||
|
4.5
|
8-K
|
001-38791
|
4.1
|
12/17/21
|
||
|
4.6
|
10-K
|
001-38791
|
4.7
|
03/1/22
|
||
|
4.7
|
10-Q
|
001-38791
|
4.1
|
08/8/24
|
||
|
4.8
|
10-Q
|
001-38791
|
4.2
|
08/8/24
|
||
|
10.1
|
8-K/A
|
001-38791
|
10.1
|
12/8/20
|
||
|
10.2
|
8-K/A
|
001-38791
|
10.5
|
12/8/20
|
||
|
10.3
|
10-K
|
001-38791
|
10.4
|
02/28/23
|
||
|
10.4†
|
8-K/A
|
001-38791
|
10.6
|
12/8/20
|
||
|
10.5†
|
DEF14A
|
001-38791
|
B
|
04/25/24
|
||
|
10.6†
|
8-K/A
|
001-38791
|
10.8
|
12/8/20
|
||
|
10.7†
|
8-K/A
|
001-38791
|
10.9
|
12/8/20
|
||
|
10.8
|
S-4/A
|
333-24878
|
Annex G
|
10/23/20
|
||
|
10.9†
|
10-Q
|
001-38791
|
10.1
|
11/9/23
|
||
|
10.10†
|
8-K
|
001-38791
|
10.1
|
06/9/23
|
||
|
10.11
|
10-K
|
001-38791
|
10.20
|
02/28/24
|
|
10.12
|
10-K
|
001-38791
|
10.21
|
02/28/24
|
||
|
10.13
|
S-3ASR
|
33-279118
|
1.3
|
05/3/24
|
||
|
10.14
|
10-Q
|
001-38791
|
10.3
|
08/8/24
|
||
|
10.15
|
10-Q
|
001-38791
|
10.4
|
08/8/24
|
||
|
10.16†
|
S-1/A
|
333-251657
|
10.13
|
01/13/21
|
||
|
10.17†
|
10-K
|
001-38791
|
10.18
|
02/28/24
|
||
|
10.18†
|
10-K
|
001-38791
|
10.24
|
03/28/25
|
||
|
10.19
|
10-K
|
001-38791
|
10.4
|
02/28/23
|
||
|
10.20†
|
10-K
|
001-38791
|
10.24
|
03/28/25
|
||
|
10.21
|
10-Q
|
001-38791
|
10.4
|
08/13/25
|
||
|
10.22*^
|
8-K
|
001-38791
|
10.1
|
05/21/25
|
||
|
10.23†
|
8-K/A
|
001-38791
|
10.1
|
05/27/25
|
||
|
10.24
|
8-K
|
001-38791
|
10.1
|
07/08/25
|
||
|
10.25†
|
8-K
|
001-38791
|
10.3
|
11/13/25
|
||
|
10.26†
|
X
|
|
10.27
|
8-K/A
|
001-38791
|
10.2
|
12/15/25
|
||
|
10.28
|
8-K/A
|
001-38791
|
10.3
|
12/15/25
|
||
|
16.1
|
8-K
|
001-38791
|
16.1
|
04/01/25
|
||
|
19.1
|
10-K
|
001-38791
|
19.1
|
03/28/25
|
||
|
21.1
|
X
|
|||||
|
24.1
|
X
|
|||||
|
31.1
|
X
|
|||||
|
31.2
|
X
|
|||||
|
32.1
|
X
|
|||||
|
97.1
|
10-K
|
001-38791
|
97.1
|
02/28/24
|
||
|
99.1
|
|
8-K
|
001-38792
|
99.1
|
02/25/26
|
|
|
99.2
|
|
8-K
|
001-38792
|
99.2
|
02/25/26
|
|
|
101.INS
|
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document .
|
X
|
||||
|
101.SCH
|
XBRL Taxonomy Extension Schema Document.
|
X
|
||||
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
X
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
X
|
||||
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document.
|
X
|
||||
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
X
|
||||
|
104
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
|
X
|
|
Luminar Technologies, Inc.
|
||
|
Date: March 26, 2026
|
By:
|
/s/ Thomas Beaudoin
|
|
Thomas Beaudoin
|
||
|
Chief Financial Officer
|
||
|
(Principal Financial and Accounting Officer)
|
||
|
Signature
|
Title
|
Date
|
||
|
/s/ Paul Ricci
|
Chief Executive Officer
|
March 26, 2026
|
||
|
Paul Ricci
|
(Principal Executive Officer)
|
|||
|
/s/ Thomas Beaudoin
|
Chief Financial Officer
|
March 26, 2026
|
||
|
Thomas Beaudoin
|
(Principal Financial and Accounting Officer)
|
|||
|
|
Director
|
March 26, 2026
|
||
|
Austin Russell
|
||||
|
/s/ Elizabeth Abrams
|
Director
|
March 26, 2026
|
||
|
Elizabeth Abrams
|
||||
|
/s/ Patricia Ferrari
|
Director
|
March 26, 2026
|
||
|
Patricia Ferrari
|
||||
|
/s/ Alec E. Gores
|
Director
|
March 26, 2026
|
||
|
Alec E. Gores
|
||||
|
/s/ Mary Lou Jepsen, PhD
|
Director
|
March 26, 2026
|
||
|
Mary Lou Jepsen, PhD
|
||||
|
/s/ Shaun Maguire, PhD
|
Director
|
March 26, 2026
|
||
|
Shaun Maguire, PhD
|
||||
|
/s/ Katharine A. Martin
|
Director
|
March 26, 2026
|
||
|
Katharine A. Martin
|
||||
|
/s/ Dominick Schiano
|
Director
|
March 26, 2026
|
||
|
Dominick Schiano
|
||||
|
/s/ Matthew J. Simoncini
|
Director
|
March 26, 2026
|
||
|
Matthew J. Simoncini
|
||||
|
/s/ Daniel D. Tempesta
|
Director
|
March 26, 2026
|
||
|
Daniel D. Tempesta
|